Marshall Wace, LLP Cullinan Oncology, Inc. Transaction History
Marshall Wace, LLP
- $63.3 Billion
- Q1 2024
A detailed history of Marshall Wace, LLP transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 47,044 shares of CGEM stock, worth $761,171. This represents 0.0% of its overall portfolio holdings.
Number of Shares
47,044
Previous 33,374
40.96%
Holding current value
$761,171
Previous $340,000
135.59%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding CGEM
# of Institutions
118Shares Held
42.8MCall Options Held
12.6KPut Options Held
4.9K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$124 Million21.33% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$55.2 Million15.23% of portfolio
-
Bvf Inc San Francisco, CA3.2MShares$51.7 Million1.63% of portfolio
-
Blue Owl Capital Holdings LP New York, NY2.92MShares$47.3 Million13.21% of portfolio
-
Franklin Resources Inc San Mateo, CA2.7MShares$43.6 Million0.02% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $738M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...